Global Metoprolol Tartrate Market, by Route Of Administration (Tablets and Injectable), by Application (Hypertension, Cardiovascular, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 6,101.4 Mn in 2022 and is expected to exhibit a CAGR of 3.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing prevalence of angina, a type of chest pain is expected to drive the global metoprolol tartrate market over the forecast period. For instance, in 2021, an article published in the Jama Network journal, which is a database of scientific references stated about the prevalence of angina among primary care patients with coronary artery disease that around 21.2% of patients experienced angina at least once monthly. Angina symptoms can be assessed in advance using established techniques, and people at higher risk can be identified and treated with medications, reducing morbidity.
Global Metoprolol Tartrate Market – Impact of Coronavirus (COVID-19) Pandemic
The most recent epidemic is the coronavirus (COVID-19) pandemic, which was initially detected on December 31, 2019, in Wuhan, China. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. According to the World Health Organization's Coronavirus Illness (COVID-19) Epidemiological Update, coronavirus disease (COVID-19) caused approximately 426 million cases and 5,899,578 fatalities in the worldwide till 20 February 2022.
Furthermore, increasing impact of COVID-19 on cardiovascular diseases is expected to drive the global metoprolol tartrate market over the forecast period. For instance, on April 21, 2021, an article published by American college of cardiology stated about the impact of COVID-19 infection on cardiovascular diseases which resulted in the pilot trial of intravenous metoprolol administration to patients with COVID-19–associated ARDS found to be safe, and reduced aggravated lung inflammation, and improved oxygenation in patients, which is expected to impel the usage of metoprolol tartrate in upcoming years.